Sequence substitutions, backbone N-heteroatom edits, lactam stapling, and C-terminal fusions can all change how fast a peptide is cleaved. They do not, by themselves, prove that biological activity is preserved. Laboratory assays can establish remaining intact peptide after a named protease challenge, remaining function after that challenge, and function of the analogue in a separate test. Those three results answer different questions. Four research articles with first-publication dates from 23 April to 31 August 2026, discussed here as of 1 October 2026, illustrate how that distinction is drawn in practice.
Side-chain, backbone, staple and terminal designs
Makambi, Chiu, Kasper, Hube and Karlsson varied K13 and K17 of histatin 5 (Hst5), a 24-amino-acid salivary peptide with activity against Candida albicans that is degraded by C. albicans secreted aspartyl proteases (Saps) and by salivary proteases (Optimizing Histatin 5). After incubation with Sap1, Sap2, Sap3 and Sap9, the K13R variant retained proteolytic stability and antifungal activity, whereas other K13 variants generally had reduced stability and activity, emphasizing a positive charge at that position. Substitutions at K17 generally enhanced proteolytic stability and improved antifungal activity after Sap incubation. A normalized intact peptide (NIP) parameter ranked variants in the presence of Saps and identified K17W as the most proteolytically stable analogue overall. Stability differences in saliva were modest; K17W was the only variant that retained more activity than Hst5 after saliva incubation. In a further assay, K17W was more effective than Hst5 at preventing biofilm formation. Remaining peptide, remaining antifungal activity after protease exposure, and biofilm prevention are related measurements, not a single endpoint.
Anwar, Cano-Sampaio and Del Valle evaluated backbone N-amino and N-hydroxy substitution as a way to disrupt protease recognition while preserving side-chain functionality, noting that many established backbone approaches impose conformational constraints that compromise biological activity (Backbone N-heteroatom substitution). On a defined chymotrypsin substrate, N-amination conferred pronounced, position-dependent protection when introduced at or adjacent to the scissile bond. On a β-sheet-forming antimicrobial peptide, poly-N-amination dramatically enhanced serum stability while preserving or enhancing conformation-dependent antibacterial activity. Serum persistence and antibacterial function were scored as separate outcomes.
Liu and colleagues built lactam-stapled scaffolds from a short semaglutide-derived GLP-1R-engaging segment, with bulky aromatic non-natural amino acid substitution (Design, synthesis, and stability evaluation). Structure-guided modelling produced 108 candidates; 35 peptides were synthesised. Most stapled analogues showed improved serum and proteolytic stability relative to semaglutide, with 11CP-17B, 11CP-17N and 11CP-19N showing the most favourable stability profiles. Molecular dynamics simulations and MM-GBSA analysis were consistent with receptor-compatible poses for representative analogues. The authors present this as a basis for subsequent functional optimisation, so stability ranking is not a completed pharmacology claim.
Pan and colleagues fused LL-37 to the C-terminus of ferritin light chain, reporting markedly enhanced structural stability and proteolytic resistance, retained antimicrobial activity in vitro and in vivo, and superior antibacterial and anti-inflammatory efficacy versus free LL-37 in a murine sepsis model (Targeted delivery of antimicrobial peptide LL-37). That construct is a terminal fusion rather than a residue swap, and a remaining-peptide metric comparable to NIP is not reported.
Assays that separate remaining peptide from remaining function
A sequence change is only as informative as the assay used to score it. Isolated proteases, mixed biological fluids, post-digest activity, and undigested functional tests support different conclusions.
| Laboratory readout | What it can establish | What it does not establish |
|---|---|---|
| Isolated protease (Saps; chymotrypsin at or adjacent to the scissile bond) | Rank-order resistance to named enzymes; position dependence of N-amination | Which enzyme dominates in saliva or serum |
| Mixed matrix (saliva, serum) | Behaviour among multiple proteases | A mechanistic cleavage map |
| Activity after pre-incubation | Whether enough active species survives the challenge | Intrinsic potency of the intact analogue |
| Function without a prior digest (biofilm; antibacterial activity; murine sepsis) | Activity of the new molecule | That slower cleavage caused the activity change |
For Hst5, remaining peptide (NIP) and antifungal activity after Sap exposure often moved together at K13, where loss of a positive charge generally reduced both. They were not identical across matrices: saliva was a weaker discriminator than isolated Saps, and only K17W retained more activity than parent Hst5 after saliva incubation. Backbone N-amination supplies a complementary split: local protection on a chymotrypsin substrate is a claim about the scissile region, whereas serum stability plus conformation-dependent antibacterial activity is a separate claim that the modification did not destroy function. For the 35 synthesised stapled analogues, improved serum and proteolytic stability is the supported experimental result; GLP-1R pharmacology is not established by that ranking alone. For the ferritin–LL-37 fusion, proteolytic resistance and retained antimicrobial activity are reported together, without a NIP-style remaining-peptide metric.
Incubation times, sample sizes and numerical half-lives are not given in these abstracts, so rank orders cannot be converted into kinetic constants here. Evidence stages include defined protease and serum incubations, C. albicans and biofilm assays, and a murine sepsis model. They do not constitute a complete cleavage-site map or a field-wide consensus.
As of 1 October 2026, one specific remaining question is whether NIP ranks from isolated Saps predict behaviour in saliva or in vivo. In the Hst5 series, saliva differences were modest even though NIP singled out K17W, so a named-protease rank order may not transfer to a mixed fluid. The stapled GLP-1R scaffolds raise a parallel point: favourable serum and proteolytic stability still leaves functional optimisation for later work.
Practical checklist when reading a proteolysis paper:
- Named enzyme versus mixed matrix (Sap isoforms, chymotrypsin, saliva, serum)
- Direct remaining-peptide metric (NIP or equivalent) versus activity after incubation
- Function of the analogue without a digest
- Whether backbone or staple chemistry was shown to preserve the conformation required for activity
- Whether a terminal fusion is being compared with a residue-level edit
That separation keeps protease resistance from being treated as a synonym for biological activity.
Frequently Asked Questions
Does a higher NIP after Sap incubation mean the analogue is more active in saliva?
Not automatically. In the Hst5 series, NIP identified K17W as the most proteolytically stable variant with Saps, but saliva stability differences were modest, and K17W was the only variant that retained more activity than Hst5 after saliva incubation.
If stapled analogues are more stable in serum than semaglutide, are they better GLP-1R ligands?
That is not established by the stability data alone. Most of the 35 synthesised stapled analogues showed improved serum and proteolytic stability relative to semaglutide; receptor-compatible poses were inferred from modelling, and functional optimisation is described as subsequent work.
Explore Further
Browse our research peptide catalog and review third-party lab reports & COAs for published batches.
---
Research use only. The information above is provided for educational and laboratory research purposes only. The compounds discussed are not approved for human or veterinary use, diagnosis, treatment, or the prevention of any disease. Nothing here is medical advice.